Biopharmx (BPMX) Shares Gap Down to $0.09

Biopharmx Corp (NYSEAMERICAN:BPMX)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $0.10, but opened at $0.09. Biopharmx shares last traded at $0.07, with a volume of 23199629 shares trading hands.

Separately, Maxim Group reissued a “buy” rating and issued a $0.40 target price on shares of Biopharmx in a research note on Tuesday, March 19th.

Biopharmx (NYSEAMERICAN:BPMX) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. The business had revenue of $0.01 million during the quarter.

A hedge fund recently raised its stake in Biopharmx stock. Deutsche Bank AG increased its position in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) by 1,256.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 549,973 shares of the biotechnology company’s stock after buying an additional 509,430 shares during the period. Deutsche Bank AG owned about 0.25% of Biopharmx worth $59,000 at the end of the most recent reporting period.

ILLEGAL ACTIVITY NOTICE: “Biopharmx (BPMX) Shares Gap Down to $0.09” was first posted by WKRB News and is the property of of WKRB News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at


BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Read More: The components of the Stochastic Momentum Index

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.